TNF antagonism seems to be particularly effective in patients with treatment-resistant depression, signs of inflammation (CRP > 5 mg/L) and elevated plasma lipids and cholesterols (Bekhbat et al., 2018). This evidence concerns the gene CRP and depressive symptom measurement.